1. Introduction {#sec1-ijms-17-02056}
===============

Cuscuta seed, Cuscutae Semen or Tu-Si-Zi, which has been widely used to nourish the liver and kidney, mainly refer to the seeds of *Cuscuta chinensis* Lam. Some phytochemical and pharmacological studies have reported the beneficial activities of Cuscuta seeds \[[@B1-ijms-17-02056]\]. For example, Cuscuta seeds have activities to improve defective kidneys \[[@B2-ijms-17-02056]\], prevent liver against damage \[[@B3-ijms-17-02056]\] and alleviate inflammation/pain \[[@B4-ijms-17-02056]\]. Crude polysaccharides from Cuscuta seeds have an immunostimulating activity \[[@B5-ijms-17-02056]\]. Alongside with the use of the seeds, the Cuscuta whole plant has also been recorded in the famous book "Shen Nong's Herbal" and some ancient medicinal books to treat dermatosis. In addition, it has been used as a folk medicine to treat adiposity or as a substitute for the Cuscuta seeds. However, no pharmaceutical study has been reported yet. In this study, *C. campestris* Yunck. whole plant was locally collected and used for the first time to examine its pharmaceutical activity.

Liver tissue injury can be caused by the ingestion of chemicals or drugs or by infection through virus infiltration \[[@B6-ijms-17-02056]\]. Among them, carbon tetrachloride (CCl~4~) is commonly used to study hepatotoxicity in animal models \[[@B7-ijms-17-02056],[@B8-ijms-17-02056]\]. CCl~4~ can be metabolized into the highly reactive trichloromethyl radical \[[@B9-ijms-17-02056]\] and then trigger lipid peroxidation \[[@B10-ijms-17-02056]\]. Therefore, blocking the lipid peroxidation can protect liver against CCl~4~-induced injury \[[@B11-ijms-17-02056],[@B12-ijms-17-02056]\]. In this study, the hepatoprotective activity of the ethanol extract of *C. campestris* whole plant (CC~EtOH~) was investigated on CCl~4~-induced chronic liver injury in mice. Once liver damage has occurred, liver marker enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) and lipid profile (total triglyceride and cholesterol) will be increased \[[@B13-ijms-17-02056]\]. Therefore, the levels of serum ALT, AST, cholesterol and triglyceride were measured in this study. In addition, liver biopsies were performed for examining the pathological changes. To elucidate the underlying mechanism of the hepatoprotective activity, the levels of malondialdehyde (MDA) and the activities of anti-oxidative enzymes (superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GRd)) in liver were also measured. Silymarin was examined as the positive control as it is a promising agent for liver protection. Our findings in this study provide evidence that *C. campestris* Yunck. whole plant possesses a hepatoprotective activity and the underlying mechanism is likely to be associated to the increase of the anti-oxidation by increasing the activities of antioxidant enzymes such as SOD, GPx and GRd.

2. Results and Discussion {#sec2-ijms-17-02056}
=========================

2.1. Effect of CC~EtOH~ on CCl~4~-Induced Hepatotoxicity {#sec2dot1-ijms-17-02056}
--------------------------------------------------------

First of all, the hepatotoxicity effect of CCl~4~ and the protective effect of CC~EtOH~ were examined using the serum of CCl~4~-induced mice. As shown in [Figure 1](#ijms-17-02056-f001){ref-type="fig"}, the CCl~4~ group exhibited significant increases of serum ALT, AST, triglyceride and cholesterol. However, these increases were obviously inhibited by treatment with CC~EtOH~ (20, 100 and 500 mg/kg) and silymarin (200 mg/kg). In addition, the inhibitions were in a dose-dependent manner. These results clearly suggested that CC~EtOH~ possess protective properties against CCl~4~-induced liver injury.

2.2. Histological Analyses {#sec2dot2-ijms-17-02056}
--------------------------

The results of hematoxylin and eosin histological analyses showed that CCl~4~ induced histological changes including increased hepatic cells cloudy swelling, cytoplasmic vacuolization, lymphocytes infiltration, hepatocellular and necrosis ([Figure 2](#ijms-17-02056-f002){ref-type="fig"}C,D) when compared to the control group ([Figure 2](#ijms-17-02056-f002){ref-type="fig"}A,B). The liver damages were reduced by treatment with CC~EtOH~ (20, 100 and 500 mg/kg) ([Figure 2](#ijms-17-02056-f002){ref-type="fig"}G--L). Since CCl~4~ induced fibrosis, Sirius Red staining was conducted and the score of liver fibrosis were examined. The results showed that the levels of inflammation and fibrosis are significantly decreased by treatment with CC~EtOH~ (100 and 500 mg/kg) ([Figure 2](#ijms-17-02056-f002){ref-type="fig"} and [Figure 3](#ijms-17-02056-f003){ref-type="fig"} and [Table 1](#ijms-17-02056-t001){ref-type="table"}). Histological examinations showed that treatment with CC~EtOH~ significantly prevents CCl~4~-induced liver injury.

2.3. Effect of CC~EtoH~ on MDA Level {#sec2dot3-ijms-17-02056}
------------------------------------

As MDA level is usually used to elucidate the level of lipid peroxidation in liver, the effects of CC~EtOH~ on CCl~4~-induced MDA production were examined. As shown in [Figure 4](#ijms-17-02056-f004){ref-type="fig"}, the level of MDA in the CCl~4~ group was dramatically increased (*p* \< 0.001) compared with the control group, however, the levels of MDA were significantly reduced by treatment with CC~EtOH~ (20, 100 and 500 mg/kg) (*p* \< 0.001) and silymarin (200 mg/kg) (*p* \< 0.001) compared with the CCl~4~ group. The results suggested that the CCl~4~-induced hepatic lipid peroxidation is reduced by CC~EtOH.~

2.4. Effect of CC~EtOH~ on Antioxidant Enzymatic Activities {#sec2dot4-ijms-17-02056}
-----------------------------------------------------------

To evaluate the antioxidant effects of CC~EtOH~, SOD, GPx and GRd were measured in the liver. The activities of these hepatic enzymes in the CCl~4~ group were dramatically decreased compared with the control group ([Figure 5](#ijms-17-02056-f005){ref-type="fig"}, [Figure 6](#ijms-17-02056-f006){ref-type="fig"} and [Figure 7](#ijms-17-02056-f007){ref-type="fig"}). However, treatment with CC~EtOH~ at the three doses and silymarin significantly increased the levels of SOD, GPx and GRd activities. The results suggested that the inhibitory effect of CCl~4~ on these hepatic enzymes was reversed by CC~EtOH~.

2.5. Phytochemical Analysis of CC~EtOH~ {#sec2dot5-ijms-17-02056}
---------------------------------------

As shown in [Figure S1](#app1-ijms-17-02056){ref-type="app"}, the HPLC chromatograms of CC~EtOH~ and the standards showed that peaks at the retention times of 17.5 and 24.5 min were hyperoside and quercetin, respectively. Two peaks showing at the retention times of 17.5 and 24.5 min were detected in the CC~EtOH~ chromatogram. The results revealed that hyperoside, quercetin and their glycosides are present in CC~EtOH~.

Cuscuta whole plant has also been used as a folk medicinal material to treat adiposity or as a substitute for the Cuscuta seeds, which have been widely used to nourish the liver and kidney in Chinese medicine. In this study, we demonstrated in the first time that the whole plant of *C. campestris* exhibits a hepatoprotective activity.

CCl~4~ has been commonly employed for the evaluation of hepatoprotective activity of different kinds of herbal extracts and drugs \[[@B8-ijms-17-02056],[@B15-ijms-17-02056]\]. CCl~4~ is thought to be transformed into trichloromethyl radicals, which are hepatotoxic metabolites. These radicals are able to react with sulfhydryl groups of glutathione (GSH) and protein. In addition, they can trigger protein oxidation and lipid peroxidation, which result in hepatocellular damage \[[@B7-ijms-17-02056],[@B12-ijms-17-02056],[@B16-ijms-17-02056]\]. In this study, CCl~4~ was used to induce chronic hepatic injury and our results revealed that the injury was significantly reduced by CC~EtOH~, clearly demonstrating that *Cuscuta campestris* possesses hepatoprotective activity.

Previous studies have shown that hepatic damage increases AST and ALT activities in the hepatocytes \[[@B16-ijms-17-02056]\] and the levels of ALT, AST, triglyceride and cholesterol in serum are increased by administering CCl~4~ to mice \[[@B13-ijms-17-02056],[@B17-ijms-17-02056],[@B18-ijms-17-02056]\]. In this study, serum ALT, AST, triglyceride and cholesterol levels were increased after CCl~4~ administration and these increases were all significantly decreased by treatment with CC~EtOH~ at three concentrations ([Figure 1](#ijms-17-02056-f001){ref-type="fig"}). In addition, histological analyses showed that hepatic cell injury induced by CCl~4~ was accompanied by fibrosis and such injury was attenuated by CC~EtOH~ ([Figure 3](#ijms-17-02056-f003){ref-type="fig"}). The quantitative histopathologic score of the fibrosis of hepatocytes showed that the fibrosis levels were significantly decreased by CC~EtOH~ (100 and 500 mg/kg; [Table 1](#ijms-17-02056-t001){ref-type="table"}). These results indicated that CC~EtOH~ can prevent liver against fibrosis.

Lipid peroxidation has been shown to be an important cause of CCl~4~-induced liver injury \[[@B10-ijms-17-02056]\]. Malondialdehyde (MDA) is the end product of the lipid peroxidation and thus commonly used as an indicator of the CCl~4~-induced liver injury \[[@B19-ijms-17-02056]\]. In this study, the increased hepatic MDA levels induced by CCl~4~ were significantly decreased by treatment of CCl~4~ ([Figure 4](#ijms-17-02056-f004){ref-type="fig"}). Therefore, these results indicated that CCl~4~ can protect the liver against CCl~4~-induced injury through inhibiting MDA production. Superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GRd) are anti-oxidative enzymes which are easily inactivated by reactive oxygen species (ROS) and lipid peroxides which are caused by CCl~4~ \[[@B16-ijms-17-02056]\]. In this study, the activities of SOD, GPx and GRd from the CCl~4~-induced injury livers were measured. The results showed that their activities were promoted by treatment with CC~EtOH~ ([Figure 5](#ijms-17-02056-f005){ref-type="fig"}, [Figure 6](#ijms-17-02056-f006){ref-type="fig"} and [Figure 7](#ijms-17-02056-f007){ref-type="fig"}), suggesting that CC~EtOH~ is able to reduce ROS production by increasing hepatic anti-oxidative enzymes activities and thus prevent the development of CCl~4~-induced liver damage. To confirm the anti-oxidative activity of the extract used in this study, the catechin-equivalent phenolics and quercetin-equivalent flavonoid concentrations of the extract were examined and determined as 58.61 ± 0.8 and 15.032 ± 1.3 mg/g CC~EtOH~, respectively. In addition, 1,1-Diphenyl-2-picrylhydrazyl (DPPH) scavenging of the extract was examined. The catechin equivalent DPPH scavenging capability was determined as 25.19 ± 0.54 mg/g CC~EtOH~ and the IC~50~ of CC~EtOH~ for DPPH scavenging is approximately 1.71 mg/mL. These results support that CC~EtOH~ containing hyperoside and quercetin has a capability to increase the anti-oxidant systems in liver. Moreover, the inhibitory effect on MDA production was also likely due to the increase in SOD, GPx and GRd activities.

Phytochemical analyses by HPLC showed that the major compounds in CC~EtOH~ are hyperoside, quercetin and flavonoid glycosides ([Figure S1](#app1-ijms-17-02056){ref-type="app"}). Although hyperoside and quercetin have been detected in both of seeds and whole plant of *C. campestris*, their amounts and the other flavonoids are different \[[@B4-ijms-17-02056],[@B20-ijms-17-02056]\]. Hyperoside have been shown to increase the level of heme oxygenase-1, an important enzyme in antioxidant defense systems to reduce oxidative stress \[[@B21-ijms-17-02056]\]. Quercetin has shown a high antioxidant activity by reducing the production of reactive oxygen species and nitric oxide \[[@B20-ijms-17-02056],[@B22-ijms-17-02056]\]. The methanol extract of the seeds of *Cuscuta chinensis* containing hyperoside, quercetin and kaempferol have been reported to increase the activities of SOD, GPx and GRd in the liver \[[@B4-ijms-17-02056]\]. Hyperoside and quercetin have been shown to exhibit hepatoprotective effect against CCl~4~-induced liver injury \[[@B23-ijms-17-02056],[@B24-ijms-17-02056]\]. Therefore, hyperoside and quercetin can be the major active constituents in CC~EtOH~ which contribute to the hepatoprotective effect.

3. Materials and Methods {#sec3-ijms-17-02056}
========================

3.1. Plant Materials and Preparation of Plant Extract {#sec3dot1-ijms-17-02056}
-----------------------------------------------------

*Cuscuta campestris* Yunck. grown on *Bidens pilosa* var. radiata was collected from Miaoli County, Taiwan. They were authenticated by Ming-Kuem Lin and Wen-Huang Peng in several aspects, including the morphology of its flowers and the chemical compositions of its seeds \[[@B20-ijms-17-02056]\]. The whole plants of *C. campestris* Yunck. were dried in a circulating air oven, and then ground. The powder (1.05 kg) was extracted with 75% ethanol three times. The filtrates were collected and concentrated with a rotary evaporator under reduced pressure. The concentrated extract was then lyophilized and weighted. The yield ratio of CC~EtOH~ (91 g) was 8.7% (*w*/*w*). The extract was stored in −20 °C before the experiments.

3.2. Chemicals {#sec3dot2-ijms-17-02056}
--------------

Silymarin, quercetin and kampferol were purchased from Sigma-Aldrich Chemical Co. (Saint Louis, MO, USA). Carboxymethylcellulose (CMC) and carbon tetrachloride (CCl~4~) was purchased from Merck Co. (Munchen, Germany). CCl~4~ was dissolved into olive oil as a 40% (*v*/*v*) solution. All other reagents used were of analytical grades (Merck Co., Munchen, Germany).

3.3. Experimental Animals {#sec3dot3-ijms-17-02056}
-------------------------

ICR male mice (18--22 g) were purchased from BioLASCO Taiwan Co., Ltd. (Taipei, Taiwan). These mice were maintained in standard cages with a 12-h:12-h light-dark cycle, relative humidity 55% ± 5%, and 22 ± 1 °C for seven days before the experiment. Food and water ad libitum were supplied by following the NIH Guide for the Care and Use of Laboratory Animals. The experimental protocol conducted in this study has been approved by the Institutional Animal Care and Use Committee, China Medical University (104-70-N; 18 December 2014).

3.4. Experimental Design of CCl~4~-Induced Hepatotoxicity {#sec3dot4-ijms-17-02056}
---------------------------------------------------------

Sixty experimental mice were randomly separated into 6 groups. For the control group and the CCl~4~ group, mice were orally administered 1% carboxymethyl cellulose (CMC). For the silymarin group, mice were orally administered silymarin (200 mg/kg in 1% CMC). For the CC~EtOH~ groups, mice were orally administered CC~EtOH~ (20, 100 and 500 mg/kg in 1% CMC). Theses oral administrations were conducted using a feeding tube with 100 μL/10 g Body Weight every day for 9 consecutive weeks. After one week of the administration of the silymarin and experimental drugs, CCl~4~ (40 μL/kg BW, 40% in olive oil) was started to inject intraperitoneally into all mice except for mice in the control group at one hour before the administration of the experimental drugs for every 3.5 days (twice a week) and 8 consecutive weeks. Thus, there were sixteen times of CCl~4~ treatment for the five CCl~4~ treated groups. The control mice received an equivalent volume of olive oil. One week after the last administration of the experimental drugs, the mice were sacrificed under anesthesia and their blood was collected for evaluation of the biochemical parameters (AST, ALT, triglyceride and cholesterol). Their liver tissues were obtained for MDA assay, histological analysis and antioxidant enzymatic activity measurements.

3.5. Serum Biochemistry {#sec3dot5-ijms-17-02056}
-----------------------

The serum was obtained as descripted previously \[[@B4-ijms-17-02056]\]. Serum ALT, AST, triglyceride and cholesterol were measured using spectrophotometric diagnostic kits (Roche, Berlin, Germany).

3.6. Histological Analysis {#sec3dot6-ijms-17-02056}
--------------------------

Histological Analysis was performed according to the method of the previous report by staining with hematoxylin and eosin \[[@B8-ijms-17-02056],[@B11-ijms-17-02056]\] and with Sirius Red \[[@B25-ijms-17-02056]\], and then observed under light microscopy (Olympus, Tokyo, Japan). For quantitative scoring of the hepatic fibrosis, the values were used according to the published method \[[@B14-ijms-17-02056]\], as the following: none: normal liver, score 0; slight: increase of collagen without formation of septa, score 1; mild: septa do not connect with each other and incomplete septa formation from portal tract to central vein, score 2; moderate: septa interconnecting completely but thin (incomplete cirrhosis), score 3; and remarkable: with thick septa (complete cirrhosis), score 4.

3.7. MDA Level as Well as Antioxidant Enzymatic Activity Measurement {#sec3dot7-ijms-17-02056}
--------------------------------------------------------------------

MDA level was determined as descripted previously using the thiobarbituric acid reacting substance method \[[@B26-ijms-17-02056]\]. SOD, GPx and GRd enzymatic activities were determined according to the published methods \[[@B27-ijms-17-02056],[@B28-ijms-17-02056],[@B29-ijms-17-02056]\]. MDA, SOD, GPx and GRd assay kits were purchased from Randox Laboratory Ltd. (Antrim, UK).

3.8. Statistical Analyses {#sec3dot8-ijms-17-02056}
-------------------------

All data were shown as mean ± SEM. SPSS statistics software program was used to do the statistical data analyses. One-way ANOVA followed by Scheffe's multiple range test was used to perform the statistical analyses. For the histological analyses, non-parametric Kruskal--Wallis test followed by the Mann--Whitney U-test was used to carry out the statistical analyses. The criterion for statistical significance was *p* \< 0.05.

3.9. Phytochemical Analysis of CC~EtOH~ by HPLC {#sec3dot9-ijms-17-02056}
-----------------------------------------------

The HPLC profile of CC~EtOH~ was determined and compared with the standard (hyperoside and quercetin), which was conducted as descripted previously \[[@B20-ijms-17-02056]\]. Quantification was performed by comparing the sample peak with the corresponding standard compound.

4. Conclusions {#sec4-ijms-17-02056}
==============

The present study clearly elucidated that CC~EtOH~ exhibited a hepatoprotective activity against CCl~4~-induced chronic liver injury in mice. The underlying mechanisms were likely the decreasing in MDA level through enhancing the activities of hepatic anti-oxidative enzymes such as GPx, GRd and SOD, and thereby the significant decrease of serum ALT, AST, triglyceride and cholesterol. In addition, fibrosis of liver was significantly reduced by CC~EtOH~. Therefore, *C. campestris* can be developed into pharmacological agents to prevent some liver disorders.
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![The effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant at low (L), middle (M) and high (H) concentrations (20, 100 and 500 mg/kg, respectively) on serum: aspartate aminotransferase (AST) (**A**); and alanine aminotransferase (ALT) (**B**) activities; and cholesterol (**C**); and triglyceride (**D**) levels in mice treated with CCl~4~. Values are mean ± SEM (*n* = 10). ^\#^ indicates significant difference from the control group (^\#\#\#^ *p* \< 0.001). \* indicates significant difference from the CCl~4~ group (\* *p* \< 0.05, \*\* *p* \< 0.01 and \*\*\* *p* \< 0.001).](ijms-17-02056-g001){#ijms-17-02056-f001}

![Hepatic histological analyses of the effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant (CC~EtOH~) on CCl~4~-induced liver damage in mice using H&E staining (40× (**A**,**C**,**E**,**G**,**I**,**K**) and 200× (**B**,**D**,**F**,**H**,**J**,**L**) magnification): (**A**,**B**) control group; (**C**,**D**) animals treated with CCl~4~; (**E**,**F**) animals treated with silymarin (200 mg/kg) and CCl~4~; and (**G**--**L**) animals treated with CC~EtOH~ (20, 100 and 500 mg/kg) and CCl~4~, respectively.](ijms-17-02056-g002){#ijms-17-02056-f002}

![Hepatic histological analyses of the effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant (CC~EtOH~) on CCl~4~-induced liver damage in mice using Sirius Red staining (40× (**A**,**C**,**E**,**G**,**I**,**K**) and 200× (**B**,**D**,**F**,**H**,**J**) magnification): (**A**,**B**) control group; (**C**,**D**) animals treated with CCl~4~; (**E**,**F**) animals treated with silymarin (200 mg/kg) and CCl~4~; and (**G**--**L**) animals treated with CC~EtOH~ (20, 100 and 500 mg/kg) and CCl~4~, respectively. Arrows indicate the fibrosis.](ijms-17-02056-g003){#ijms-17-02056-f003}

![The effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant on malondialdehyde (MDA) content in mice treated with CCl~4~. Values are mean ± SEM (*n* = 10). ^\#^ indicates significant difference from the control group (^\#\#\#^ *p* \< 0.001). \* indicates significant difference from the CCl~4~ group (\*\*\* *p* \< 0.001).](ijms-17-02056-g004){#ijms-17-02056-f004}

![The effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant on superoxide dismutase (SOD) activity in mice treated with CCl~4~. Values are mean ± SEM (*n* = 10). ^\#^ indicates significant difference from the control group (^\#\#^ *p* \< 0.01). \* indicates significant difference from the CCl~4~ group (\* *p* \< 0.05, \*\* *p* \< 0.01 and \*\*\* *p* \< 0.001).](ijms-17-02056-g005){#ijms-17-02056-f005}

![The effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant on glutathione peroxidase (GPx) activity in mice treated with CCl~4~. Values are mean ± SEM (*n* = 10). ^\#^ indicates significant difference from the control group (^\#\#\#^ *p* \< 0.001). \* indicates significant difference from the CCl~4~ group (\* *p* \< 0.05, \*\* *p* \< 0.01 and \*\*\* *p* \< 0.001).](ijms-17-02056-g006){#ijms-17-02056-f006}

![The effects of silymarin and the ethanol extracts of *Cuscuta campestris* whole plant on glutathione reductase (GRd) activity in mice treated with CCl~4~. Values are mean ± SEM (*n* = 10). ^\#^ indicates significant difference from the control group (^\#\#\#^ *p* \< 0.001). \* indicates significant difference from the CCl~4~ group (\* *p* \< 0.05, \*\* *p* \< 0.01 and \*\*\* *p* \< 0.001).](ijms-17-02056-g007){#ijms-17-02056-f007}

ijms-17-02056-t001_Table 1

###### 

Quantitative the protective effects of silymarin and CC~EtOH~ on CCl~4~-induced hepatic fibrosis based on histological analyses using Sirius Red staining ^1^.

  Group                       Histopathologic Score of Liver Fibrosis   
  --------------------------- ----------------------------------------- --------------
  Normal                      0                                         0.7 ± 0.3
  CCl~4~                      1.6 ± 0.5                                 2.9 ± 0.8
  Silymarin/CCl~4~            1.4 ± 0.5                                 1.5 ± 0.5 \*
  CC~EtOH~ 20 mg/kg/CCl~4~    1.4 ± 0.5                                 2.1 ± 0.9
  CC~EtOH~ 100 mg/kg/CCl~4~   1.2 ± 0.4                                 2.3 ± 0.7
  CC~EtOH~ 500 mg/kg/CCl~4~   1.1 ± 0.5 \*                              1.9 ± 0.6 \*

^1^ Hepatic fibrosis was scored 0--4 according to the method of Ruwart et al. \[[@B14-ijms-17-02056]\] as mentioned in the Materials and Methods; ^2^ The scores were obtained by the following calculation: the sum of the number per grade of affected mice/the total number of examined mice (*n* = 9--10); ^3^ The final Sirius Red positive area (%) was calculated by Image-Plus and was divided the sum of the number per SR positive area (%) of affected mice by the total number of examined mice (*n* = 9--10). \* Statistically significant difference between CCl~4~ group and drug-treated groups at *p* \< 0.05.

[^1]: These authors contributed equally to this work.
